Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: John O'Neill who wrote (13819)	1/27/1998 11:39:00 PM
From: Henry Niman	Respond to of 32384

JO, Although it's hard to tell by looking at LGND's recent price performance, I think that a merger would be a major plus to companies like LGND, who are grossly underfunded and have many compounds ready for clinical trials (and have many alliances). The trials and product launches are very expensive, which is one of the drivers of the mergers. The biggest of course is AHP/SBH, but the mere discussion of the merger should have push other companies into the merger mode (LLY and WLA were mentioned in the WSJ this weekend, and such a merger could have a major impact on the rexinoid/TZD diabetes/metabolic disease areas). Mergers will eliminate duplication of services and allow companies to focus and increase R&D. LGND has non-overlapping alliances with AHP and SBE, and a merger shgould accelerate those programs, as well as future programs. For AHP, that list is quite extensive. They have licensed progestin agonists and antagonists (see the AHP archives at home.att.net ) and the SERMs have many applications beyond osteoporosis. A merger should allow AHP to develop these markets more quickly.